Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody
about
Targeting CD8 T-Cell Metabolism in TransplantationCo-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?Update on CD40 and CD154 blockade in transplant modelsCD28 co-stimulation in T-cell homeostasis: a recent perspectiveTargeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cellsAdvantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28Immunotherapeutic strategies in autoimmune uveitisPreclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationAnti-CD28 Antibody-Initiated Cytokine Storm in Canines.Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domainPharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future.Primate models in organ transplantationCostimulation Blockade in Kidney Transplantation: An UpdateT-cell co-stimulatory blockade in transplantation: two steps forward one step back!Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade.Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway.Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.CD28 Costimulation: From Mechanism to Therapy.Cytokines: The Good, the Bad, and the Deadly.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Role of Memory T Cells in Allograft Rejection and ToleranceAnti-CD28 Antibody and Belatacept Exert Differential Effects on Mechanisms of Renal Allograft Rejection.CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity.Preclinical Testing of Antihuman CD28 Fab' Antibody in a Novel Nonhuman Primate Small Animal Rodent Model of Xenogenic Graft-Versus-Host Disease.Reply to "Biologics in organ transplantation".First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.Selective CD28 Blockade Results in Superior Inhibition of Donor-Specific T Follicular Helper Cell and Antibody Responses Relative to CTLA4-Ig.Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses.Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival.FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft.Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates
P2860
Q26777941-17AC5B2E-5060-44BE-A5D0-82B1E732D247Q26796099-DB086C79-456C-466F-B320-E7EEBEAE7D61Q26798362-5FD80096-F64B-4CD0-AB4C-C2A1E2308502Q27007031-0A2804BB-F320-4514-9554-59721C6CD373Q27340853-37B1CE14-20E6-476B-8000-BEF81E81E4E2Q33573593-E139CBDC-9EB1-439D-920B-35EE2C7904D5Q34274950-B6F5B554-7C69-41E0-BD60-9FEDEDB31613Q34803897-4C76D636-D2AB-48B7-8A22-847FC5ACE6B0Q35586614-459F6A4B-D7B5-40B2-925C-06F70EDB9DA8Q35610659-766EC01E-AFA0-4390-A6FA-78ADB9F8724AQ36293855-2B613E34-F2CD-4B6E-AA21-B71FA4A5A509Q36588716-4EF44095-CF79-476A-8C04-CF7A181ACD6DQ36980277-CF377409-C881-49E3-A292-BB41CBC13271Q37122367-22D908D4-631E-4DC5-A2C3-3FF0BAB8636FQ37375148-ABD0364D-F74F-4143-80F0-321628E424D9Q38148197-3DE8C7C0-04A7-4C28-96AE-ED8F114F5485Q38237428-3D9F9D1F-29A7-4C95-A0C0-BEFE4019A546Q38681685-1B2E16DB-115C-41B7-A286-8CE4EFB9C9D1Q38824724-1877CE2F-64B7-4AA0-A28C-0D49BAA00F25Q38827908-D7094C21-3F44-4A26-85AC-EF0E456C6D35Q38837466-1EEF0506-1D3F-481E-AF9B-8480F705B203Q39002175-F4FAD33B-2F87-492C-A89D-8C90D6B71191Q39161011-DB1CE84F-C2BF-4FDF-98DF-795CD0CB0571Q39178547-F1E1BF1A-04DF-40AF-9760-FAA1FB6FC387Q39782306-132ACC80-F62F-4355-B12A-4A3DCB337C88Q41916538-4473BC79-684A-4B16-8616-BFFC0985A58CQ46458062-B18C2FD1-608D-4472-86F7-1CA69D1D015CQ46541185-74174527-AA60-4771-BFD2-0A2879A05520Q48223745-18243464-5D98-45E9-98BC-D4AB81C2CE19Q48747887-F8D2A9A0-183D-4B8E-A5E6-2F9E3425B578Q49598430-203BA8F2-AC25-45C5-9EF4-B6085659F04FQ50101803-6D4771F8-0011-49AB-A8AE-142AF27DBD88Q51026715-476018D0-4511-47CF-851A-718ED9443FDCQ54937398-74ADCF44-6BDD-4538-B55F-72588EF0082CQ56889641-09682998-E8E2-4FCC-8868-0E5D0B04B69A
P2860
Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody
description
im Juli 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 03 July 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2012
@uk
name
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@en
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@nl
type
label
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@en
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@nl
prefLabel
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@en
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@nl
P2093
P2860
P1476
Preclinical efficacy and immun ...... -CD28 monovalent Fab' antibody
@en
P2093
P2860
P304
P356
10.1111/J.1600-6143.2012.04164.X
P407
P577
2012-07-03T00:00:00Z